# CHAPTER I INTRODUCTION

#### **1.1 Research Background**

Acute respiratory infections (ARI), such as bronchopneumonia, are one of the most common diseases in the community. WHO in 2020 reported that the highest disease in developing countries is bronchopneumonia, which causes death in children. Based on WHO data, the incidence of pneumonia infection in Indonesia among under-fives is estimated to be between 10 and 20% per year. Data from the Ministry of Health of the Republic of Indonesia 2021 in 2020 show that bronchopneumonia respiratory infections in children that occurred in East Java had the 5th largest position in Indonesia at 42.9%.<sup>1</sup> According to the respondent's data report, the second largest disease that occurred in Tidar Magelang Hospital in 2023 was ARI bronchopneumonia, with a total of 2,493 patients. In cases that occurred in Magelang City Hospital, bronchopneumonia has not decreased until now. Based on the Magelang city government profile, Magelang is categorized as a wet climate area with high rainfall. This leads to high humidity, causing bacteria, viruses, and fungi to prolifer-ate <sup>2</sup>.

Bronchopneumonia is an ARI disease caused by microorganisms such as viruses, fungi, and bacteria. ARI bronchopneumonia is an acute respiratory infection that affects the lungs. Inflammation of the lung parenchyma occurs from the bronchi to the alveoli.<sup>3</sup> The lungs are made up of tiny sacs called alveoli that are filled with air. A person suffering from bronchopneumonia has the bronchi and alveoli filled with pus and fluid, making breathing painful and limiting oxygen intake <sup>4</sup>.

<sup>&</sup>lt;sup>1</sup> RI Kemenkes, "Profil Kesehatan Indonesia 2020," *Kementrian Kesehatan Republik Indonesia* 139 (2021).

<sup>&</sup>lt;sup>2</sup> Ludfi Yusela, Muhammad Ali Sodik, and STIKes Surya Mitra Husada, "Kondisi Faktor-Faktor Lingkungan Fisik Rumah Dengan Kejadian Pneumonia Pada Anak Balita," *Jurnal STIKes Surya Mitra Husada* (2018): 1–7.

<sup>&</sup>lt;sup>3</sup> Andy Samuel, "Bronkopneumonia on Pediatric Patient," *Journal Agromed Unila* 1, no. 2 (2014): 185–189.

<sup>&</sup>lt;sup>4</sup> Sakila Ersa Putri Hts and Dika Amalia, "Bronkopenmonia," Jurnal Medika Nusantara 1, no. 3 (2023): 134–145.

ARI bronchopneumonia is common in pediatrics and is one of the leading causes of death in children under five. WHO data states that ARI bronchopneumonia accounts for 14% of all deaths in children under 5 years old<sup>5</sup>. According to the WHO, bronchopneumonia contributed to 5.50% of under-five deaths worldwide in 2019<sup>6</sup>. The disease is more common in children under 5 years of age, as the immune system of paediatrics is still developing. Therefore, pediatricians are more likely to experience bronchopneumonia<sup>7</sup>.

In hospitalized paediatric bronchopneumonia ARI patients, there is a potential risk of drug toxicity that is of particular concern to medical personnel so that it can harm patients<sup>8</sup>. Unintended drug-related problems (DRPs) in treatment can result in dangerous clinical outcomes. The factors that cause DRPs are polypharmacy, comorbidities, and length of hospital stay<sup>9</sup>. The higher prevalence of bronchopneumonia ARI will contribute to the high incidence of DRPs. The classification of DRP, according to Cipolle includes indication without drug, drug without indication, inappropriate drug selection, dose too high, dose too low, adverse drug reactions, and patient non-compliance<sup>10</sup>. DRP, according to Cipolle, is more commonly used in Indonesia<sup>11</sup>, while DRP, according to PCNE, is more complicated and takes a long time<sup>12</sup>.

In treating the disease, there needs to be an effort to be healthy for the patient. In the hadith, it is explained that Allah commands humans to seek treatment because

<sup>&</sup>lt;sup>5</sup> World Health Organization, *The WHO STEPwise Approach to Surveillance* (World Health Organization. Regional Office for Europe, 2021).

<sup>&</sup>lt;sup>6</sup> Nader A. Fawzy et al., "A Systematic Review of Trials Currently Investigating Therapeutic Modalities for Post-Acute COVID-19 Syndrome and Registered on WHO International Clinical Trials Platform," *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases* 29, no. 5 (May 2023): 570–77,

<sup>&</sup>lt;sup>7</sup> Sriwati Palaguna, "Bronkopneumonia Pada Anak Umur Nol Sampai Satu Tahun Dan Asap Rokok," *Jurnal Ilmiah Ecosystem* 23, no. 2 (2023): 501–509.

<sup>&</sup>lt;sup>8</sup> Yohanes Ayele and Zelalem Tilahun Tesfaye, "Drug-Related Problems in Ethiopian Public Healthcare Settings: Systematic Review and Meta-Analysis," *SAGE Open Medicine* 9 (2021): 205031212110097.

 <sup>&</sup>lt;sup>9</sup> Yohanes Ayele and Zelalem Tilahun Tesfaye, "Drug-Related Problems in Ethiopian Public Healthcare Settings: Systematic Review and Meta-Analysis," SAGE Open Medicine 9 (January 2021)
<sup>10</sup> Sylvi Adiana, "Klasifikasi Permasalahan Terkait Obat (Drug Related Problem/DRPs)," Indonesian Journal of Health Science 2, no. 2 (2022): 54–58.

<sup>&</sup>lt;sup>11</sup> Benjamin J Basger, Rebekah J Moles, and Timothy F Chen, "Development of an Aggregated System for Classifying Causes of Drug-Related Problems," *Annals of Pharmacotherapy* 49, no. 4 (2015): 405–418.

<sup>&</sup>lt;sup>12</sup> Carita Linden-Lahti1, 2\*, Anna Takala1, Anna-Riia Holmström1 and Marja Airaksinen1, *Applicability of Drug-related Problem (DRP) Classification System for Classifying Severe Medication Errors*, 743rd ed., vol. 23 (BMC Health Services Research, 2023).

all diseases have a cure except old age and death. This is the same as human action to eliminate hunger, cover himself with a cause of the cold, etc. Allah reminds us in the Qur'an about effort and not despair in treatment in order to achieve the goal of treatment therapy<sup>13</sup>. As described in the Muslim hadith, namely

لِكُلِّ دَاءٍ دَوَاءٌ فَإِذَا أُصِيبَ دَوَاءُ الدَّاءِ بَرَأَ بِإِذْنِ اللَّهِ عَزَّ وَجَلَّ

"Every disease has a cure. If the cure of a disease is right, it will heal with the permission of Allah SWT" (HR. Muslim).

When we get the gift of sickness, we should not stay silent without trying to recover, but we are guided to try as much as possible to recover from the disease. When the disease is treated with the proper treatment, it will be able to maximize the treatment<sup>14</sup>. The high incidence of bronchopneumonia ARI disease means that researchers want to evaluate a treatment by optimizing treatment that can reduce the incidence of DRPs, which has a harmful and detrimental impact on patients.

#### **1.2 Research Problems**

The problem formulations in this research are

1. What is the treatment description of pediatric bronchopneumonia ARI patients hospitalized at Tidar Hospital?

2. What is the potential incidence of DRP in the treatment of inpatient pediatric bronchopneumonia ARI patients at Tidar Hospital?

#### **1.3 Research Objectives**

The objectives of this research are

1. To describe the treatment of pediatric bronchopneumonia ARI inpatients at Tidar Hospital.

2. To determine the potential incidence of DRP in the treatment of inpatient pediatric bronchopneumonia at Tidar hospital.

<sup>&</sup>lt;sup>13</sup> Elin Yulinah Sukandar, "Tren Dan Paradigma Dunia Farmasi," *Bandung: Departemen Farmasi FMIPA ITB* (2006).

<sup>&</sup>lt;sup>14</sup> Abu Al-Husain Muslim An-Nisabury, "Bin Al-Hajjaj Bin Muslim al-Qusyairi," *Shahih Muslim. Beirut: Daar al-Kutub al-Ilmiyah* (1992).

### **1.4 Research Benefits**

### **1.4.1 Theoritical Benefits**

The benefits of this study can be used to assist in improving patient treatment patterns and achieving the desired therapeutic effect.

# **1.4.2 Practical Benefits**

The results of this study are expected to add insight and knowledge so as to improve treatment guidelines related to bronchopneumonia, ARI disease, and the role of clinical pharmacy in Tidar Hospital.

# **1.5 Authenticity Research**

Research on DRPs has been conducted by several researchers, as shown in Table 1 below.

tients in the Inpatient In- stallation of RSUP dr. M. Djamil Pa- dang <sup>15</sup> Drug Related Observa- Problem in tion patients with Drug Related Observa- Problem in tion						
Analysis of DRPs (Drug tionObserva- tionDepend- ent varia- ble:Medication-related problems in geriatric pneumonia patients in- clude inappropriate medications in 3 cases (1.82%), inappropriate medicationsAnother study Variable: Geriat- ric Pneumonia, DRPs Method: Cross- Sectional DRP, according DRP, according DRP, according DRP, according DRP, according DRP, according DRP, according DRP, according to PCNE V5.1 Indicators Dipro servational DRP according tion of stallation of Bayer at a dag15Real Study Variable: Geriat- ric Pneumonia, DRPs DRP, according to PCNE V5.1 Indicators Dipro Sectional DRP, according to PCNE V5.1 Indicators Dipro Sectional DRP accord Indicators Dipro across sective (1.21%), and interaction issues, spective Data col- lection technique: Purposive samplingAnother study Variable: Geriat- ric Pneumonia, DRPs DRPs Sectional DRP accord Indicators Dipro Indicators: Broncho- pneumonia treatment therapy guide actions in 133 cases (81.09%).Another study Variable: Sectional DRPs DRPs Sectional DRP accord Indicators: Broncho- pneumonia treatment therapy guide lines accord ing to WH and Tid Hospital Med scape, ISO.Drug Related Problem in patients withObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs) 		• •	Variable	Result	Differences in	n research
Analysis of DRPs (Drug tionObserva- tonDepend- ent varia- ble:Medication-related problems in geriatric pneumonia patients in- clude inappropriate medications in 3 cases (1.82%), inappropriate duplication of active substances without clear indications in 3 cases (1.82%), medications be: Drug Related Prob- lems) in Geri- atric Pneu- monia Pa- tients in the Djamil Pa- dang <sup>15</sup> Variable: method: ent varia- be: DRPsVariable: geriatrics uplication of active substances outplications in 3 cases (4.87%), medications ot acses (1.82%), clear indications but not treated in 14 cases too high doses and/or frequencies and/or frequencies in 14 cases (8.53%), dosage issues including too high doses and/or frequencies spective (1.21%), and interaction issues, specifically potential drug inter- actions in 133 cases (81.09%).Variable: Variable: Drug Related Observa- poster toon technique: Purposive samplingDepend- ent varia- be:Drug Related Problems (DRPs) problem in tionVariable: period period preumonia problem in be:Variable: period preumonia problem in patients withVariable: period problem in toonVariable: period preumonia problem in patients withVariable: period preumonia problem in problem in problem in problem in problem in problem in problem in patients withDepend- ent varia- be:Drug Related Problems (DRPs) problem in priod preumonia preumoniaVariable: problem in problem in toonDepend- ent varia- problem in problem in toonDepend- ent varia- problem in toonDepend- ent varia- problem in 	uue	Kesearch			A noth on study	Deel Study
DRPs (Drug Related Prob- lems) in Geri- atric Pneu- monia Pa- tients in the stallation of All agestionent varia- ble: nia thera- py and geriatricsgeriatric pneumonia patients in- clude inappropriate medications in 3 cases (1.82%), inappropriate mulcication of active substances without clear indications in 3 tasses (1.82%), clear indications to PCNE V5.1ric Pneumonia, ISPA, Pediat rics, DRPs Method: Cross- Sectional DRP, according to PCNE V5.1Broncho- pneumonia to PCNE V5.1Inpatient In- stallation of Djamil Pa- dang <sup>15</sup> Independ- test NRPs (8.53%), dosage issues including to high doses and/or frequencies in 1 case (0.60%), too low doses and/or frequencies in 2 cases (1.21%), and interaction issues, spective technique: Purposive samplingBroncho- pneumoniaDrug Related Problem in patients withObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs) amounted to 50 cases with the category of indication withoutVariable: Pneu- monia, DRPVariables: Broncho- pneumonia	Analysis of	Observe	Damand	Madiantian valated machlema in		
Related Prob- lems) in Geri- atric Pneu- monia Pa- tients in the Balalition of All agesble: clude inappropriate medications in 3 cases (1.82%), inappropriate duplication of active substances in 8 cases (4.87%), medications without clear indications in 3 tasses (1.82%), clear indications but not treated in 14 cases 2015, PDPI 2003, ISO, and Indicators: ISO, and Indicators: Broncho- pneumonia treatment therapy guide lines accord in 1 case (0.60%), too low doses and/or frequencies in 2 cases (1.21%), and interaction issues, specifically potential drug inter- actions in 133 cases (81.09%).DRPs Method: Cross- Sectional DRP, according to PCNE V5.1 Indicators Dipro Servational DRP accord Indicators: Broncho- pneumonia treatment therapy guide lines accord ing to WHG and Tida Hospital Mec scape, ISO.Drug Related Problem in patients withObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs) amounted to 50 cases with the category of indication withoutVariable: Pneu- monia, DRPVariables: Broncho- pneumonia			-	-		
lems) in Geri- atric Pneu- monia Pa- tients in the Djamil Pa- dang <sup>15</sup> Pneumo- nia thera- py and geriatricsin 3 cases (1.82%), inappropriate duplication of active substances in 8 cases (4.87%), medications to PCNE V5.1 Indicators Dipro 2015, PDPI 2003, ISO, and Iso, and Brocho- pneumonia treatment therapy guide lines accord ing to Cipolle technique: Purposive samplingMethod: Cross- Sectional DRP, according to PCNE V5.1 Indicators Dipro 2015, PDPI 2003, ISO, and drug.com websiteISPA, Pedia rics, DRPs sectional DRP, according to PCNE V5.1 Indicators Dipro 2015, PDPI 2003, ISO, and drug.com websiteISPA, Pedia rics, DRPs sectional DRP, according to PCNE V5.1 Indicators Dipro 2015, PDPI 2003, ISO, and drug.com websiteDigmil Pa- dang <sup>15</sup> Research method: in 1 case (0.60%), too low doses and/or frequencies in 2 cases (1.21%), and interaction issues, specifically potential drug inter- actions in 133 cases (81.09%).Method: Cross- Sectional Drug Related Problems (DRPs)Indicators tor Support treatment therapy guide lines accord ing to WH0 and Tida Hospital Mec scape, ISO.Drug Related problem in patients withDepend- ent varia- ble:Drug Related Problems (DRPs) amounted to 50 cases with the category of indication withoutVariable: Pneu- monia, DRP All agesVariables: Broncho- pneumonia	· · ·	tion				
atric Pneu- monia Pa- tients in the Inpatient In- stallation of Big and in 8 cases (4.87%), medications in 8 cases (4.87%), medications without clear indications in 3 to PCNE V5.1 Indicators Dipro Super Stallation of RSUP dr. M. Djamil Pa- dang <sup>15</sup> rics, DRPs Method: De scriptive of tases (1.82%), clear indications but not treated in 14 cases to high doses and/or frequencies and/or frequencies in 2 cases (1.21%), and interaction issues, spective Data col- lection technique: Purposive samplingspecifically potential drug inter- actions in 133 cases (81.09%).Sectional DRP, according to PCNE V5.1 Indicators Dipro 2015, PDPI 2003, ISO, and drug.com websiterics, DRPs Method: De servational DRP accord ing to Cipolle Indicators: Broncho- pneumonia treatment therapy guide lines accord ing to WHG and Tida Hospital Med scape, ISO.Drug Related Problem in patients withObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs) amounted to 50 cases with the actegory of indication withoutVariable: Pneu- monia, DRP All agesVariables: Broncho- pneumonia						
monia Pa- tients in the Inpatient In- stallation of Djamil Pa- dang <sup>15</sup> py and geriatricsin 8 cases (4.87%), medications in 8 cases (4.87%), medications in 3 to PCNE V5.1Method: De scriptive of scriptive of DRP accord Indicators Dipro 2015, PDPI 2003, ISO, and drug.com websiteMethod: De scriptive of servational DRP accord ing to Cipolle Indicators: Broncho- pneumonia treatment therapy guide lines accord ing to WHG and Tida Horspital Mec scape, ISO.Depend- ent varia- be:py and geriatricsin 8 cases (4.87%), medications in 3 cases (1.82%), clear indications in 14 cases 2015, PDPI 2003, ISO, and drug.com websiteMethod: De scriptive of servational DRP accord ing to Cipolle Indicators: Broncho- pneumonia treatment therapy guide lines accord ing to WHG and Tida Hospital Mec scape, ISO.Drug Related Problem in patients withObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs) of indication withoutVariable: Pneu- monia, DRP All agesVariables: Broncho- pneumonia						· ·
tients in the Inpatient In- stallation of ent varia- ble: DRPs Research ang <sup>15</sup> method: dang <sup>15</sup> Retro- spective Clain of the constraint o			nia thera-			,
Inpatient In- stallation of RSUP dr. M.Independ- ent varia- ble: DRPscases (1.82%), clear indications in to t treated in 14 cases (8.53%), dosage issues including too high doses and/or frequencies and/or frequencies in 2 cases spective (1.21%), and interaction issues, Data col- lection 	monia Pa-		py and	in 8 cases (4.87%), medications	DRP, according	
stallation of RSUP dr. M.ent varia- ble: DRPsbut not treated in 14 cases (8.53%), dosage issues including too high doses and/or frequencies in 1 case (0.60%), too low doses Retro- and/or frequencies in 2 cases spective (1.21%), and interaction issues, Data col- lection technique: Purposive samplingDury Related Problem in tionDepend- ent varia- ble:Drug Related Problems (DRPs) amounted to 50 cases with the and considered with the cases with the monia, DRPVariable: Broncho- pneumonia treatmentVariable: Broncho- pneumonia treatmentVariable: Broncho- pneumonia treatment	tients in the		geriatrics	without clear indications in 3	to PCNE V5.1	scriptive ob-
RSUP dr. M. Djamil Pa- dang <sup>15</sup> ble: DRPs Research method:(8.53%), dosage issues including too high doses and/or frequencies in 1 case (0.60%), too low doses and/or frequencies in 2 cases spective (1.21%), and interaction issues, Data col- specifically potential drug inter- lection technique: Purposive samplingISO, and in 1 case (0.60%), too low doses method:ISO, and drug.com websiteing to Cipolle Indicators: Broncho- pneumonia treatment therapy guide lines actions in 133 cases (81.09%).Drug Related Problem in patients withObserva- ble:Depend- ent varia- ble:Drug Related Problems (DRPs) amounted to 50 cases with the category of indication withoutVariable: Pneu- monia, DRP All agesVariables: Broncho- pneumonia	Inpatient In-		Independ-	cases (1.82%), clear indications	Indicators Dipro	servational
Djamil Pa- dang <sup>15</sup> Research method:too high doses and/or frequencies in 1 case (0.60%), too low doses and/or frequencies in 2 cases spective (1.21%), and interaction issues, Data col- lection technique: Purposive samplingdrug.com websiteIndicators: Broncho- pneumonia treatment therapy guide lines accord ing to WHG and Tida Hospital Med scape, ISO.Drug Related Problem in patients withObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs) action withoutVariable: Pneu- monia, DRP All agesVariables: Broncho- pneumonia	stallation of		ent varia-	but not treated in 14 cases	2015, PDPI 2003,	DRP accord-
dang15method:in 1 case (0.60%), too low dosesBroncho- pneumoniaRetro- spectiveRetro- and/or frequencies in 2 cases spectiveBroncho- pneumoniaData lection samplingDepend- ent varia- ble:Drug Related Problems (DRPs)Variable: Pneu- monia, DRPVariables: Pneu- Broncho- pneumoniaDrug Related patients withObserva- ble:Depend- ent varia- ble:Drug Related Problems (DRPs)Variable: Pneu- monia, DRPVariables: Pneu- monia, DRP	RSUP dr. M.		ble: DRPs	(8.53%), dosage issues including	ISO, and	ing to Cipolle
dang15method:in 1 case (0.60%), too low dosesBroncho- pneumoniadang15Retro- spectiveand/or frequencies in 2 cases spectiveBroncho- pneumoniaData col- lection technique: Purposive samplingDepend- ent varia- ble:Drug Related Problems (DRPs)Variable: Pneu- monia, DRPVariables: Pneu- monia, DRPDrug Related patients withObserva- ble:Depend- ent varia- ble:Drug Related Problems (DRPs)Variable: Pneu- monia, DRPVariables: Pneu- monia, DRP	Djamil Pa-		Research	too high doses and/or frequencies	drug.com website	Indicators:
Retro- spectiveand/or frequencies in 2 cases (1.21%), and interaction issues, pata col- lection technique: Purposive samplingpneumonia treatment therapy guide lines actions in 133 cases (81.09%). technique: Purposive samplingpneumonia treatment therapy guide lines accord ing to WHG and Tida Hospital Med scape, ISO.Drug Related Problem in patients withObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs) to 50 cases with the monia, DRP All agesVariables: Broncho- pneumonia			method:		8	Broncho-
spective Data col- lection technique: Purposive sampling(1.21%), and interaction issues, specifically potential drug inter- actions in 133 cases (81.09%). technique: Purposive samplingtreatment therapy guide lines accord ing to WHG and Tida Hospital Med scape, ISO.Drug Related Problem in patients withObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs) amounted to 50 cases with the monia, DRP All agesVariables: Broncho- pneumonia	0		Retro-			pneumonia
Data col- lection technique: Purposive samplingspecifically potential drug inter- actions in 133 cases (81.09%). technique: Purposive samplingtherapy guide lines accord ing to WHG and Tida Hospital Med scape, ISO.Drug Related Problem in patients withDepend- ent varia- ble:Drug Related Problems (DRPs) to 50 cases with the monia, DRP All agesVariables: Broncho- pneumonia			spective	-		1
lection technique: Purposive samplingactions in 133 cases (81.09%).lines accord ing to WHG and Tida Hospital Med scape, ISO.Drug Related Problem in patients withDepend- ent varia- ble:Drug Related Problems (DRPs) to 50 cases with the amounted to 50 cases with the monia, DRP All agesVariables: Broncho- pneumonia			-			
technique: Purposive samplingtechnique: Purposive samplinging to WHG and Tida Hospital Med scape, ISO.Drug Related Problem in patients withObserva- ent varia- ble:Drug Related Problems (DRPs) amounted to 50 cases with the monia, DRP All agesVariables: Broncho- pneumonia						
Purposive samplingand Tida Hospital Med scape, ISO.Drug Related Problem in patients withDepend- ent varia- ble:Drug Related Problems (DRPs) to 50 cases with the monia, DRP All agesVariables: Broncho- pneumonia						
samplingHospital Med scape, ISO.Drug RelatedObserva- tionDrug Related Problems (DRPs)Variable: Pneu- monia, DRPVariables: Broncho- pneumoniapatients withble:category of indication withoutAll agesPneumonia						
Drug Related Problem in patients withDepend- ent ble:Drug Related Problems (DRPs) amounted to 50 cases with the category of indication withoutVariable: Pneu- Broncho- pneumoniaVariables: Broncho- pneumonia						
Drug RelatedObserva- tionDepend- ent varia- ble:Drug Related Problems (DRPs)Variable: Pneu- monia, DRPVariables: Broncho- pneumonia			sampning			-
Problem in patients withtion ent varia- ble:ent varia- categoryamounted to<						scape, ISO.
Problem in patients withtion ent varia- ble:ent varia- categoryamounted to<	Drug Related	Observa-	Depend-	Drug Related Problems (DRPs)	Variable: Pneu-	Variables
patients with ble: category of indication without All ages pneumonia	U		-	<b>e</b>		
		uon			· · ·	
province is a province medication 11 areas (22.0%) Sampling meth ISDA DDD	pneumonia at		OTT A	medication 11 cases (22.0%)	Sampling meth-	ISPA, DRP,
	- ·					
Jasa Kartini nia patient including indications for pulmo- od: consecutive pediatrics	Jasa Karumi		ma patient	menualing mateauons for pulmo-	ou. consecutive	pediatrics

## Table 1 Authenticity Research

<sup>15</sup> Endang Agustina et al., "Analisis DRPS (Drug Related Problems) Pada Pasien Geriatri Pneumonia Di Instalasi Rawat Inap RSUP Dr. M. Djamil Padang," *Jurnal Farmasi Higea* 15, no. 1 (2023): 84–92.

Research title	Type of Research	Variable	Result	Differences in research	
Tasikmalaya city hospital <sup>16</sup>		therapy Independ- ent varia- ble: DRPs Research method: retrospec- tive Sampling technique: consecu- tive sam- pling	nary tuberculosis, diarrhea, and hypertension; medication without indication 0 cases; underdose in eight cases (16.0%) including Analsik, Largactil, Alganax, Sanmol, Ketorolac, Risperidon, ranitidine; overdose in 12 cases (24.0%) including Tracetat, Sanmol Syrup, Codipront, Citico- lin, Lansoprazole, Lancid, Furo- semide; wrong medication 0 cas- es; drug interaction 19 cases (38.0%) with major category (10.5%), moderate (68.4%), and minor (21.1%); and harmful medication 0 cases.	Another study sampling. DRP according to PCNE V9.1	Real Study Sampling method: pur- posive sam- pling DRP accord- ing to Cipolle
Identification of Drug Re- lated Prob- lems (DRPs) in Pediatric Patients with Community- Acquired Pneumonia in the Inpatient Installation of RSD Madani, Central Sula- wesi Prov- ince <sup>17</sup>	Observa- tion	Depend- ent varia- bles: CAP, pe- diatrics, inpatient Independ- ent varia- bles: DRPs Research method: prospec- tive Data col- lection technique: random sampling	The research results obtained from 28 patients showed the number of DRP incidents in the inappropriate medication catego- ry was 1 case (1.7%), drug inter- actions were 35 cases (58.3%), underdose of medication was 18 cases (30%), overdose of medica- tion was 6 cases (10%), and med- ication without indication was 0 cases (0%).	Variables: CAP, DRP Method: Prospec- tive DRP according to Cip- olle/helper/strand 1990 Indicators: Brit- ish National Formulary for Children Drug Interaction Checker (Med- scape) and Drug Interaction Facts.	Variables: Acute Res- piratory Infec- tion (ARI) bronchopneu- monia, DRP Retrospective Method DRP accord- ing to Cipolle 2004 Broncho- pneumonia treatment guidelines according to WHO and- Tidar Hospi- tal, Medscape, and ISO.

 <sup>&</sup>lt;sup>16</sup> Nur Rahayuningsih, Amalia Rahayu, and Muharam Priatna, "Drug Related Problems in Patients with Pneumonia at Jasa Kartini Tasikmalaya City Hospital," *Pharmacy Education* 23, no. 2 (2023)
<sup>17</sup> Putu Maharani Ajeng Astiti, Alwiyah Mukaddas, and Safarudin Atho Illah, "Identifikasi Drug Related Problems (DRPs) Pada Pasien Pediatri Pneumonia Komunitas Di Instalasi Rawat Inap RSD Madani Provinsi Sulawesi Tengah," *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)* 3, no. 1 (2017): 57–63.